Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a fixed combination of follitropin alfa and lutropin alfa compared to human menopausal gonadotropin hMG in Japanese women with luteinizing hormone LH and follicle stimulating hormone FSH deficiency undergoing assisted reproductive technology ART. The study focuses on women who are premenopausal and wish to conceive, addressing fertility challenges related to these hormone deficiencies. This is a Phase 3 interventional trial with a randomized, parallel-group design. Participants will be assigned to one of two groups one receiving a fixed combination of recombinant follitropin alfa and lutropin alfa in a 21 ratio, and the other receiving hMG. Both treatments are administered daily by subcutaneous injection during ovarian stimulation, up to 18 days. Additional medications include daily cetrorelix acetate starting on Day 5 or 6 of stimulation to prevent premature ovulation, and coriongonadotropin alfa for final follicular maturation. After oocyte retrieval, participants will self-administer progesterone gel intravaginally for luteal phase support. During the study, participants will undergo assessments such as ultrasound scans to monitor follicle development, hormone level evaluations, and semen analysis of the male partner. Researchers will track the total number of oocytes retrieved, dosage and duration of gonadotropin treatment, embryo development, pregnancy rates, and safety outcomes including adverse events and ovarian hyperstimulation syndrome. The total study duration is about 5.5 months for those not becoming pregnant and up to 13 months for those with confirmed pregnancy.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the study medicine elranatamab, alone and combined with daratumumab, in people with multiple myeloma who have previously been treated with therapies including lenalidomide. The trial aims to determine whether elranatamab offers more benefit compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone, while also assessing the safety and activity of elranatamab with daratumumab. This is a Phase 3, randomized, open-label study designed to compare these treatment options and to evaluate infection protection measures. The study includes three parts. Part 1 tests the safety and activity of different doses of elranatamab combined with daratumumab. In Part 2, participants are randomly assigned to receive elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 assesses the impact of enhanced infection protection in participants receiving elranatamab alone or with daratumumab. Treatments are administered subcutaneously or orally as appropriate, and participants continue treatment until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular assessments including monitoring of disease progression, safety evaluations, and adverse event tracking. Key outcome measures include dose-limiting toxicities, progression-free survival, and treatment-emergent adverse events. Other evaluations include overall survival, response rates, duration of response, pharmacokinetics, immunogenicity, and quality of life assessments. Follow-up and monitoring continue for up to 51 months after randomization to capture long-term effects and safety.
Actively Recruiting
Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.
1-10 of 19
1